Cargando…

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant

BACKGROUND: Epidermal growth factor receptor (EGFR) has emerged as an important therapeutic target. Overexpression of EGFR is frequently observed in hepatocellular carcinoma (HCC) and EGFR activation has been proven to be a potential determinant of primary resistance of HCC cells to sorafenib. In ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sueangoen, Natthaporn, Tantiwetrueangdet, Anchalee, Panvichian, Ravat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076995/ https://www.ncbi.nlm.nih.gov/pubmed/32190291 http://dx.doi.org/10.1186/s13578-020-00407-1

Ejemplares similares

Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues
por: Panvichian, Ravat, et al.
Publicado: (2015)

TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues
por: Panvichian, Ravat, et al.
Publicado: (2015)

PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2021)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
por: Saifon, Woraseth, et al.
Publicado: (2022)

MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
por: Jakobsen, K R, et al.
Publicado: (2017)

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling
por: Wang, Qiang, et al.
Publicado: (2020)

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]
Publicado: (2021)

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]
Publicado: (2021)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
por: Kibirova, Albina, et al.
Publicado: (2019)

Blocking ERK1/2 signaling impairs TGF-β1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells
por: Sritananuwat, Phaijit, et al.
Publicado: (2017)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
por: Van Der Steen, Nele, et al.
Publicado: (2020)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
por: Wang, Xiaoyuan, et al.
Publicado: (2018)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
por: Robles-Oteiza, Camila, et al.
Publicado: (2021)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy
por: Silva, Catarina Oliveira, et al.
Publicado: (2016)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways
por: Tito, Claudia, et al.
Publicado: (2023)

Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
por: Romero-Ventosa, Elena Yaiza, et al.
Publicado: (2015)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
por: Ma, Lichun, et al.
Publicado: (2015)

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
por: Ayeni, Deborah, et al.
Publicado: (2019)

EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism
por: Chen, Xing-Chen, et al.
Publicado: (2017)

JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor
por: Zhang, Fu-quan, et al.
Publicado: (2015)

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib
por: Jin, Qian, et al.
Publicado: (2021)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen, Kim-Son H, et al.
Publicado: (2012)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_53fei53imtclpq1159i49kfr81